Navigation Links
Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug

TSX-V: PGA

VANCOUVER, May 07, 2007 /PRNewswire-FirstCall/ - Pacgen Biopharmaceuticals Corporation ("Pacgen") is pleased to report that topline results from its Phase I/II study of PAC-113, a novel antifungal, show it is generally safe, well-tolerated, and active in the treatment of oral Candida infection with clinical cure rates comparable to the current standard of care. Based on these results the Company plans to initiate a Phase IIb study to optimize PAC-113 dose and formulation.

"For many immunocompromised patients oral candidiasis can be severe, impacting their ability to get appropriate nutrition. We are very encouraged by the PAC-113 results and its potential to help patients with oral candidiasis, particularly when available treatments have a number of limitations and drawbacks," said Dr. Neil Reiner, Professor and Head of Division of Infectious Diseases, UBC Department of Medicine and Vancouver General Hospital, and a member of Pacgen's Clinical Advisory Board

PAC-113 is a peptide based anti-fungal drug candidate targeting oral Candida infections in immunocompromised patients and patients with salivary dysfunction. The Phase I/II clinical trial of PAC-113 was conducted at sites in the United States and South Africa and recruited over 100 HIV seropositive patients with oral candidiasis.

The objective of this study was to provide safety data for PAC-113, as well as to establish first proof of efficacy for PAC-113 in eliminating clinical signs and symptoms of oral candidiasis. This Phase I/II study was a comparison between PAC-113 mouthrinse and Nystatin oral suspension. The study was a randomized, examiner-blinded, parallel design clinical trial that included a 14-day treatment phase, and a 14-day follow-up period, with a day 28 follow-up visit. Analyses were conducted on patients who were at least 80% compliant in the treatment phase.

Topline results show that 37% of PAC-113
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/31/2014)... Mass. , July 31, 2014  Decision Resources ... technology market intelligence product Marketrack to now include ChinaTrack; ... device landscape in an interactive dashboard providing detailed ... procedure volumes at a hospital level. Other ... , Updated data feed: In addition to end-user surveys ...
(Date:7/31/2014)... July 31, 2014 Lazarus Effect, a medical ... devices to facilitate removal of blood clots, announced the ... financing will support EU commercialization of several approved Lazarus ... Lazarus ReCover™ and Lazarus Cover™ in the ... investor confidence in the value of our novel, platform ...
(Date:7/31/2014)... 31, 2014 Catylix, Inc. ( ... Milpitas, California ) announced today the ... commercialize new fluorination products and related chemistry. ... from the use of substituents that are chemically ... polarity to improve binding and bioavailability. Fluorinated functional ...
Breaking Medicine Technology:Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Lazarus Effect Closes $5 Million Financing 2Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2
... WOONSOCKET, R.I. , Jan. 12 CVS Caremark Corporation (NYSE: ... increase in its quarterly dividend of approximately 15%, to 8.75 cents ... 2010 to holders of record on January 22, 2010 . This ... up 4.5 cents per share from the previous rate of ...
... , , BETHESDA, Md. , ... in biotechnology for diabetes therapy, and a provider of technical ... companies, today announced the completion of patient enrollment in its ... the safety and efficacy of D-tagatose as an oral treatment ...
Cached Medicine Technology:CVS Caremark Corporation Increases Quarterly Dividend 15% 2Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes 2Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes 3Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes 4Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes 5
(Date:7/31/2014)... 2014 The team at Advanced ... NJ, is proud to announce that they are ... PMR proudly offers many services, including Physical Therapy, ... medical supplies. Some of their physical therapy services ... geriatric therapy among a vast list of others. ...
(Date:7/31/2014)... In a front-page story, the Wall ... & Johnson, is withdrawing its laparoscopic power morcellator due ... This important story has also been reported by ... AP (7/30), the Pittsburgh Business Times (7/30) and TIME ... uterine procedures to, “slice up common uterine masses called ...
(Date:7/31/2014)... , Rest assured, there is a happy ending, ... shows that many college students are stressed out and ... there are simple ways for students to relieve stress ... of UC,s Health Promotion and Education Program. The trouble ... a whole array of different stress-management techniques college students ...
(Date:7/31/2014)... The Never Give Up 26 Foundation looks forward to seeing ... Simply bring your ticket and Mention Never Give Up 26 ... and family. , Packy had unique internal drives, ... optimism continues to impact the lives of many. Overcoming ... a happy life was truly a testament to his character. ...
(Date:7/31/2014)... The “Nucleic Acid Isolation and Purification ... bead based), Consumables & Instruments, by Application (Plasmid ... users - Global Forecasts to 2018” provides a ... opportunities, current market trends, and strategies impacting the ... with the estimates and forecasts of the revenue ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs' Approved, Advanced Physical Medicine and Rehabilitation Now Offering Chiropractic & Podiatric Services 2Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 2Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 3Health News:Simple tips to fend off freak-outs 2Health News:Simple tips to fend off freak-outs 3Health News:Don't Forget To Mention Never Give Up 26 Foundation 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 4
... that has been commissioned by the Australian government states that ... cost effective option to control// the growing epidemic of childhood ... found the various programs based in schools were cost-effective, but ... that many ministers for state who are in favour of ...
... Canada can differ according to provinces, says a new study ... ,People on dialysis in Alberta were four times more ... the study conducted over a five-year period found. Saskatchewan, Atlantic ... for kidneys than Ontario. ,"We can say that ...
... The National Institute of Virology in Pune declared Tuesday there ... 250 km from here in south Gujarat.// ,Additional ... samples from Surat city, and not even a single sample ... NIV, have not yet clarified why two persons had died ...
... August 26 issue of "The Lancet" has revealed that ... past decade// in many countries of the world, especially ... University of Auckland, New Zealand, and colleagues repeated the ... between 2002-2003 to assess the global prevalence of asthma, ...
... a Christchurch General Practitioner for allegedly manipulating a sexual ... account, the GP even bought her lingerie and advised ... ,The doctor has been slapped with a charge ... with the woman in question. Allegedly, the former ...
... Board has indicated that the Klein Government is all set ... early stage breast cancer.// The spokeswoman of the board, Lee ... trials in the United Kingdom before advising the $40,000-per-patient drug ... is available to those patients who are in dire need ...
Cached Medicine News:Health News:Health Experts In Australia Toy With The Idea Of Surgery for Controlling Obesity In Teenagers 2Health News:Rise In Childhood Allergies 2
7 mm curved blade. Round handle....
7 mm strong curved blade. Round handle....
3 mm diameter roller blade, 15 mm from angle to tip. Round handle....
No. 4. 0.75 mm wide x 5 mm long, lightly curved tip, offset to the left. Hexagonal handle....
Medicine Products: